Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Toraymyxin PMX-20R** is a single-use extracorporeal hemoperfusion cartridge designed for the selective removal of endotoxin from circulating blood in patients with sepsis or septic shock associated with Gram-negative bacterial infection or endotoxemia[1][2][4][5][7]. Its mechanism utilizes **polymyxin B** immobilized on polystyrene derivative fibers to adsorb and bind endotoxins, preventing their systemic effects[1][4][5][7]. While polymyxin B is a potent antibiotic, its systemic use is limited by nephrotoxicity and neurotoxicity; immobilization on the cartridge enables safe extracorporeal removal of circulating endotoxins[1][4]. The device is indicated for use alongside standard medical care in intensive care settings and requires compatible hemodialysis or continuous renal replacement therapy (CRRT) equipment[4][5]. Clinical data indicate Toraymyxin improves hemodynamics, decreases vasopressor requirements, may improve oxygenation, and can reduce organ dysfunction and mortality in septic shock patients[1][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Toraymyxin PMX-20R.